OpGen (OPGN) Competitors $4.73 -0.03 (-0.63%) As of 07/2/2025 03:50 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsShort InterestTrendsBuy This Stock OPGN vs. CORBF, DCGO, SERA, XGN, EUDA, NAKA, KDLY, QIPT, ATPC, and PIIIShould you be buying OpGen stock or one of its competitors? The main competitors of OpGen include Global Cord Blood (CORBF), DocGo (DCGO), Sera Prognostics (SERA), Exagen (XGN), EUDA Health (EUDA), KindlyMD (NAKA), Kindly MD (KDLY), Quipt Home Medical (QIPT), Agape ATP (ATPC), and P3 Health Partners (PIII). These companies are all part of the "healthcare" industry. OpGen vs. Its Competitors Global Cord Blood DocGo Sera Prognostics Exagen EUDA Health KindlyMD Kindly MD Quipt Home Medical Agape ATP P3 Health Partners Global Cord Blood (NYSE:CORBF) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends. Is CORBF or OPGN more profitable? Global Cord Blood has a net margin of 0.00% compared to OpGen's net margin of -1,140.36%. Company Net Margins Return on Equity Return on Assets Global Cord BloodN/A N/A N/A OpGen -1,140.36%N/A -287.58% Does the media prefer CORBF or OPGN? In the previous week, Global Cord Blood had 1 more articles in the media than OpGen. MarketBeat recorded 1 mentions for Global Cord Blood and 0 mentions for OpGen. Global Cord Blood's average media sentiment score of 0.00 equaled OpGen'saverage media sentiment score. Company Overall Sentiment Global Cord Blood Neutral OpGen Neutral Which has stronger valuation and earnings, CORBF or OPGN? Global Cord Blood has higher revenue and earnings than OpGen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlobal Cord Blood$196.12M0.90$79.04MN/AN/AOpGen$2.67M17.82-$32.67MN/AN/A Do institutionals & insiders hold more shares of CORBF or OPGN? 2.7% of OpGen shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by insiders. Comparatively, 43.8% of OpGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, CORBF or OPGN? Global Cord Blood has a beta of -0.66, indicating that its stock price is 166% less volatile than the S&P 500. Comparatively, OpGen has a beta of -1.68, indicating that its stock price is 268% less volatile than the S&P 500. SummaryGlobal Cord Blood beats OpGen on 6 of the 9 factors compared between the two stocks. Get OpGen News Delivered to You Automatically Sign up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPGN vs. The Competition Export to ExcelMetricOpGenMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.62M$21.96M$5.54B$8.87BDividend YieldN/A119.72%5.39%4.10%P/E RatioN/AN/A26.2319.90Price / Sales17.826.74413.23113.66Price / CashN/AN/A36.1356.90Price / Book-0.410.218.045.38Net Income-$32.67M-$27.15M$3.15B$248.50M7 Day Performance-2.67%-0.89%1.44%2.04%1 Month Performance3.96%1.32%3.62%4.84%1 Year Performance80.53%4.03%34.68%20.23% OpGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPGNOpGenN/A$4.73-0.6%N/A+80.5%$47.62M$2.67M0.00100Upcoming EarningsGap DownCORBFGlobal Cord BloodN/A$1.50flatN/A+45.0%$182.33M$196.12M0.001,200DCGODocGo2.1137 of 5 stars$1.57-1.9%$3.56+126.8%-47.5%$163.17M$616.55M-78.504,407News CoveragePositive NewsSERASera Prognostics1.4467 of 5 stars$2.77-32.3%N/A-56.2%$154.08M$80K-2.95120Gap DownHigh Trading VolumeXGNExagen3.2236 of 5 stars$6.98-0.3%$7.50+7.4%+291.6%$149.10M$55.64M-8.31220EUDAEUDA Health0.7764 of 5 stars$3.58+4.4%N/A-5.6%$127.45M$4.01M0.002Gap DownNAKAKindlyMDN/A$13.85-3.0%N/AN/A$86.10M$2.72M0.00N/AKDLYKindly MDN/A$14.28-2.7%N/A+518.6%$85.99M$2.47M-18.55N/AGap DownQIPTQuipt Home Medical2.922 of 5 stars$1.79-0.6%$2.85+59.2%-42.9%$78.20M$245.91M-8.521,200ATPCAgape ATP0.2936 of 5 stars$1.32flatN/A-65.5%$66.01M$1.32M-2.2040Positive NewsPIIIP3 Health Partners3.336 of 5 stars$6.30-1.1%$16.25+157.9%-72.4%$45.79M$1.50B-0.13500News CoveragePositive News Related Companies and Tools Related Companies CORBF Competitors DCGO Competitors SERA Competitors XGN Competitors EUDA Competitors NAKA Competitors KDLY Competitors QIPT Competitors ATPC Competitors PIII Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPGN) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OpGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPGN Stock Alerts